• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

There's No Reason to Give Up on Pfizer

Why? Consistency.
By STEPHEN GUILFOYLE
Feb 02, 2021 | 11:00 AM EST
Stocks quotes in this article: PFE, VTRS, BNTX, MRNA

For me, Pfizer (PFE) is one of those names that once you buy, you may never sell. Because it's such a good name to hold? Hmm... yes and no. The real answer is in consistency. There are much better names for traders looking for beta. There are very few names that can spend a long time on one's book, while never hitting either a target price nor a panic point. Pfizer is one of those names. Why don't we just give up? No reason. Especially if the firm pays you $1.56 a year per share, or 4.36% just to hang around. 4.36% might not seem like a lot, but it beats your losers, and it sure beats the bank.

For the firm's fourth quarter, Pfizer reported adjusted EPS of $0.42. That missed Wall Street's projections by a nickel. GAAP EPS came to just $0.10. Revenues landed at $11.68 billion, up 11.8% year over year, and a solid beat of expectations as well. It was during this period that Pfizer completed the deal spinning off the Upjohn business unit in combination with Mylan to form what is now Viatris (VTRS) . Pfizer has been moving toward focusing on core businesses for several years now.

Under The Hood

Oncology is Pfizer's largest business, featuring such drugs as Ibrnace for the treatment of breast cancer, and Vyndaqel which is a heart medication. The unit experienced 23% sales growth, contributing $3.024 billion in sales to the whole. Other units experiencing significant growth were Vaccines for obvious reasons... at +17% to $2.001 billion, and Rare Disease. That unit grew 26% to $865 million. More stagnant, but still large contributing business units include Internal Medicine at $2.308 billion (+1%), Hospital at $2.22 billion (+8%), and Inflammation & Immunology at $1.267 billion (+1%).

As for the BNT 162b2 vaccine that was developed alongside German biotech BioNTech (BNTX) to combat the SARS-Cov-2 virus that causes Covid-19, Q4 sales amounted to $154 million which boosted overall performance for the Vaccines unit. The firm expects to sell roughly $15 billion worth of this vaccine this year and has increased forward looking guidance accordingly.

Adjusted net income increased 15% for the quarter to $2.366 billion. Backing out of the adjustment, net income improved to $594 million from an outright loss for Q4 2019.

Looking Ahead

After accounting for sales of the firm's Covid-19 vaccine, the firm now sees full year 2021 revenue of $59.4 billion to $61.4 billion versus the $56.36 billion that the street had in mind. The firm also increased FY 2021 adjusted EPS guidance from $3.00 to $3.10, to $3.10 to $3.20. The caveat there would be that the increased range still leaves the midpoint below the $3.19 that Wall Street's sell-side seems to be expecting.

On a positive note, a study conducted by the firm showed that the more contagious strains of Covid-19 that have been first identified in the UK and in South Africa, showed only a small impact on the effectiveness of this Pfizer vaccine. Moderna (MRNA) showed somewhat similar results. This appears to be a bit better than what we have heard from some other vaccine developers. I do not know if this is an advantage of messenger RNA technology over other vaccine development technologies or not, but certainly bears watching.

Pfizer is already working on a "booster" shot to protect against new variants of SARS-Cov-2 as they arise, as is Moderna.

The Chart

What we see here, I think, is a closing pennant or flag, but it's not clean. The lower trend line can be drawn all the way back to last spring's market collapse. The upper trend line has been a sharp decline of less than two months. I would expect this to produce some increased volatility. Given that the shares are very close to being technically oversold, my feeling is that the general direction upon the closing of this pennant will be in a northerly direction, but keep in mind that I am long the shares and potentially biased.

What we look for now is for the shares to retake and hold that 200 day line at $34.73. For me, this is an add at these prices. Once this piece is published, I expect to add to my long. My panic point is the $32 low of late October. My target remains for now unchanged at $48. Unless these shares trade either that low, or that high, I see no reason to make a sale. My net basis is just above the $33 level.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Stephen Guilfoyle was Long PFE, MRNA equity.

TAGS: Drug Approvals | Earnings | Investing | Markets | Stocks | Technical Analysis | Trading | Healthcare | Pharmaceuticals | Coronavirus

More from Investing

Nuvalent Has Begun the Bottoming Process

Bruce Kamich
Jul 1, 2022 10:52 AM EDT

Let's check the charts and indicators.

You Can Invest in Micron, But Here's Why You May Want to Wait

Stephen Guilfoyle
Jul 1, 2022 10:15 AM EDT

MU reported earnings Thursday night and the guidance was shocking.

The Charts Point to More Selling Ahead for 4 Former Tech Leaders

Ed Ponsi
Jul 1, 2022 10:00 AM EDT

Keep in mind that no matter how much a stock has fallen, it can always go lower, and it appears these four stocks could prove that point.

Enanta Pharmaceuticals Bounces Off a Key Support Level Once Again

Bruce Kamich
Jul 1, 2022 9:41 AM EDT

The shares of the biotech company appear to be finding a bottom but could use more sideways action to create a better base.

CRISPR Therapeutics Has Turned the Corner

Bruce Kamich
Jul 1, 2022 8:43 AM EDT

Here's our current price target.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 07:59 PM EDT PAUL PRICE

    Very good quarterly numbers from Bassett Furniture (BSET)

    Bassett Furniture (BSET) blew right through analys...
  • 04:41 PM EDT PAUL PRICE

    First Half Results - Putrid Second Half Results - Likely to Be Much Better

    It's great that we're done with June. 2022 marked...
  • 04:51 PM EDT PAUL PRICE

    We Should Be in for Better Starting Soon

    Window dressing Thursday, the last day of the...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login